Oyster Therapeutics raised USD 60 million in Series A-2 financing led by 4BIO Capital. Eli Lilly, Actium Group, CE Ventures and TOHO Ventures joined existing investors including Syncona, Oxford Science Enterprises, Mission BioCapital and MGB Ventures. The London company, previously known as Kesmalea Therapeutics, develops targeted protein degraders for neurological diseases. The capital will advance an oral tau degrader toward clinical development and support its SELFTAC platform. Oyster’s programmes remain preclinical, and the announcement does not report completed human efficacy. The company also adopted the Oyster name alongside the financing.
Oyster Therapeutics raises USD 60m for neuroscience drug development
4BIO Capital leads the Series A-2 financing.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


